Literature DB >> 23566930

Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia.

Damon A Bell1, Robert Bender, Amanda J Hooper, Jenny McMahon, Glenn Edwards, Frank M van Bockxmeer, Gerald F Watts, John R Burnett.   

Abstract

BACKGROUND: Familial hypercholesterolaemia (FH) is an autosomal dominant condition characterised by increased low density lipoprotein cholesterol (LDL-c), xanthomata and premature cardiovascular disease. However, it is currently underdiagnosed and undertreated in Australasia. We sought to investigate whether interpretative commenting on lipid profiles could improve FH detection and treatment.
METHODS: A case-historical control study of individuals with serum LDL-c concentrations ≥6.5 mmol/L; 96 cases receiving an interpretative comment suggesting FH compared with 100 controls not receiving a comment.
RESULTS: Serum LDL-c was repeated in 63 (66%) cases and 70 (70%) controls within 12 months. LDL-c decreased in 59 (94%) cases and in 61 (87%) controls. In individuals with a repeat LDL-c, a mean LDL-c reduction of 2.3 mmol/L (32%; p<0.0001) was demonstrated in controls, compared with 3.0 mmol/L (42%; p<0.0001) in cases; significantly greater than that of controls (p<0.005). Interpretative comments suggesting specialist review were associated with a higher referral rate compared with controls (11.5% vs 1%, p<0.05).
CONCLUSION: Interpretative commenting was associated with a significant additional LDL-c reduction and increased specialist referrals compared with controls. However, only a minority of individuals received a specialist referral. Interpretative commenting may play an important role in the detection and management of FH.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566930     DOI: 10.1016/j.cca.2013.03.027

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  Knowns and unknowns in the care of pediatric familial hypercholesterolemia.

Authors:  Andrew C Martin; Samuel S Gidding; Albert Wiegman; Gerald F Watts
Journal:  J Lipid Res       Date:  2017-07-12       Impact factor: 5.922

2.  Introducing genetic testing with case finding for familial hypercholesterolaemia in primary care: qualitative study of patient and health professional experience.

Authors:  Luisa Silva; Laura Condon; Nadeem Qureshi; Brittany Dutton; Stephen Weng; Joe Kai
Journal:  Br J Gen Pract       Date:  2022-06-30       Impact factor: 6.302

Review 3.  Strategies for screening for familial hypercholesterolaemia in primary care and other community settings.

Authors:  Nadeem Qureshi; Maria Luisa R Da Silva; Hasidah Abdul-Hamid; Stephen F Weng; Joe Kai; Jo Leonardi-Bee
Journal:  Cochrane Database Syst Rev       Date:  2021-10-07

Review 4.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

5.  An online questionnaire survey of UK general practitioners' knowledge and management of familial hypercholesterolaemia.

Authors:  See Kwok; Jing Pang; Safwaan Adam; Gerald F Watts; Handrean Soran
Journal:  BMJ Open       Date:  2016-11-09       Impact factor: 2.692

Review 6.  Systematic Identification of Familial Hypercholesterolaemia in Primary Care-A Systematic Review.

Authors:  Luisa Silva; Nadeem Qureshi; Hasidah Abdul-Hamid; Stephen Weng; Joe Kai; Jo Leonardi-Bee
Journal:  J Pers Med       Date:  2021-04-15

7.  An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".

Authors:  Jing Pang; Miao Hu; Jie Lin; Takashi Miida; Hapizah M Nawawi; Jeong Euy Park; Xue Wu; Anis S Ramli; Ngoc Thanh Kim; See Kwok; Lourdes E Gonzalez-Santos; Ta-Chen Su; Thanh Huong Truong; Handrean Soran; Shizuya Yamashita; Brian Tomlinson; Gerald F Watts
Journal:  BMJ Open       Date:  2017-10-25       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.